Literature DB >> 25651836

Nonsense suppression therapies in ocular genetic diseases.

Xia Wang1, Cheryl Y Gregory-Evans.   

Abstract

Premature termination codons (PTCs) are caused by nonsense mutations and this leads to either degradation of the mutant mRNA template by nonsense-mediated decay (NMD) or the production of a non-functional, truncated polypeptide. PTCs contribute significantly to inherited human diseases including ocular disorders. Nonsense suppression therapy allows readthrough of PTCs, thereby rescuing the production of a full-length functional protein. In this review, we highlight the mechanisms that are involved in discriminating normal translation termination from premature termination codons; the current understanding of nonsense-mediated mRNA decay models (NMD); the association and crosstalk between PTC and the underlying dynamic NMD process; and the suppression therapies that have been employed in nonsense-medicated ocular disease models. Defining the mechanistic complexity of PTC and NMD will be important to improve treatments of the numerous genetic disorders caused by PTC mutations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25651836     DOI: 10.1007/s00018-015-1843-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  55 in total

1.  GTP hydrolysis by eRF3 facilitates stop codon decoding during eukaryotic translation termination.

Authors:  Joe Salas-Marco; David M Bedwell
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 2.  Nonsense-mediated mRNA decay of collagen -emerging complexity in RNA surveillance mechanisms.

Authors:  Yiwen Fang; John F Bateman; Julian F Mercer; Shireen R Lamandé
Journal:  J Cell Sci       Date:  2013-05-31       Impact factor: 5.285

Review 3.  Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon.

Authors:  W P Tate; E S Poole; J A Horsfield; S A Mannering; C M Brown; J G Moffat; M E Dalphin; K K McCaughan; L L Major; D N Wilson
Journal:  Biochem Cell Biol       Date:  1995 Nov-Dec       Impact factor: 3.626

4.  Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects.

Authors:  Cheryl Y Gregory-Evans; Xia Wang; Kishor M Wasan; Jinying Zhao; Andrew L Metcalfe; Kevin Gregory-Evans
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

Review 5.  Regulation of cytoplasmic mRNA decay.

Authors:  Daniel R Schoenberg; Lynne E Maquat
Journal:  Nat Rev Genet       Date:  2012-03-06       Impact factor: 53.242

6.  Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.

Authors:  M Manuvakhova; K Keeling; D M Bedwell
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

7.  Regulation of nonsense-mediated mRNA decay: implications for physiology and disease.

Authors:  Rachid Karam; Jordan Wengrod; Lawrence B Gardner; Miles F Wilkinson
Journal:  Biochim Biophys Acta       Date:  2013-03-13

8.  Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Eitan Kerem; Michael W Konstan; Kris De Boeck; Frank J Accurso; Isabelle Sermet-Gaudelus; Michael Wilschanski; J Stuart Elborn; Paola Melotti; Inez Bronsveld; Isabelle Fajac; Anne Malfroot; Daniel B Rosenbluth; Patricia A Walker; Susanna A McColley; Christiane Knoop; Serena Quattrucci; Ernst Rietschel; Pamela L Zeitlin; Jay Barth; Gary L Elfring; Ellen M Welch; Arthur Branstrom; Robert J Spiegel; Stuart W Peltz; Temitayo Ajayi; Steven M Rowe
Journal:  Lancet Respir Med       Date:  2014-05-15       Impact factor: 30.700

9.  Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.

Authors:  Igor Nudelman; Annie Rebibo-Sabbah; Marina Cherniavsky; Valery Belakhov; Mariana Hainrichson; Fuquan Chen; Jochen Schacht; Daniel S Pilch; Tamar Ben-Yosef; Timor Baasov
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

10.  A novel MIP gene mutation associated with autosomal dominant congenital cataracts in a Chinese family.

Authors:  Yibo Yu; Yinhui Yu; Peiqing Chen; Jinyu Li; Yanan Zhu; Yi Zhai; Ke Yao
Journal:  BMC Med Genet       Date:  2014-01-09       Impact factor: 2.103

View more
  11 in total

Review 1.  Conserved genetic pathways associated with microphthalmia, anophthalmia, and coloboma.

Authors:  Linda M Reis; Elena V Semina
Journal:  Birth Defects Res C Embryo Today       Date:  2015-06-03

2.  Nonsense mutations in the rhodopsin gene that give rise to mild phenotypes trigger mRNA degradation in human cells by nonsense-mediated decay.

Authors:  Ramon Roman-Sanchez; Theodore G Wensel; John H Wilson
Journal:  Exp Eye Res       Date:  2015-09-26       Impact factor: 3.467

3.  Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.

Authors:  Kim M Keeling
Journal:  Diseases       Date:  2016-10-19

4.  Use of PTC124 for nonsense suppression therapy targeting BMP4 nonsense variants in vitro and the bmp4st72 allele in zebrafish.

Authors:  Max Krall; Stephanie Htun; Anne Slavotinek
Journal:  PLoS One       Date:  2019-04-24       Impact factor: 3.240

5.  Spectrum of mutations in the RB1 gene in Vietnamese patients with retinoblastoma.

Authors:  Nguyen Cong Kiet; Le Thai Khuong; Do Duc Minh; Nguyen Huynh Minh Quan; Phan Thi Xinh; Nguyen Ngoc Chau Trang; Nguyen Thanh Luan; Nguyen Minh Khai; Hoang Anh Vu
Journal:  Mol Vis       Date:  2019-04-04       Impact factor: 2.367

6.  Stop codons and the +4 nucleotide may influence the efficiency of G418 in rescuing nonsense mutations of the HERG gene.

Authors:  Haiyun Yu; Yanhai Meng; Shuhong Zhang; Chen Tian; Fang Wu; Ning Li; Qiuyang Li; Yulan Jin; Jielin Pu
Journal:  Int J Mol Med       Date:  2019-10-01       Impact factor: 4.101

7.  Mutation spectrum of RB1 mutations in retinoblastoma cases from Singapore with implications for genetic management and counselling.

Authors:  Swati Tomar; Raman Sethi; Gangadhara Sundar; Thuan Chong Quah; Boon Long Quah; Poh San Lai
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

8.  A Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome.

Authors:  Lucy S French; Carla B Mellough; Fred K Chen; Livia S Carvalho
Journal:  Front Cell Neurosci       Date:  2020-07-09       Impact factor: 5.505

Review 9.  The genetic architecture of aniridia and Gillespie syndrome.

Authors:  Hildegard Nikki Hall; Kathleen A Williamson; David R FitzPatrick
Journal:  Hum Genet       Date:  2018-09-22       Impact factor: 4.132

Review 10.  Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia.

Authors:  Monica Borgatti; Emiliano Altamura; Francesca Salvatori; Elisabetta D'Aversa; Nicola Altamura
Journal:  J Clin Med       Date:  2020-01-21       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.